End point of clinical trials - PDFSEARCH.IO - Document Search Engine

End point of clinical trials
Results: 145

#	Item
1	Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (BCC): 24-month update of the pivotal ERIVANCE BCC study A Sekulic,1 MR Migden,2 AE Oro,3 L Dirix,4 K Lewis,5 JD Hainsworth,6 Add to Reading List Source URL: www.curis.com Language: English - Date: 2014-05-12 19:51:02 Histopathology End point of clinical trials Response Evaluation Criteria in Solid Tumors Vismodegib Medicine Basal-cell carcinoma Carcinoma
2	PDF Document Add to Reading List Source URL: axelar.se Language: English - Date: 2014-12-10 04:47:01 Non-small-cell lung carcinoma Kaplan–Meier estimator Squamous-cell carcinoma End point of clinical trials Neutropenia Medicine Oncology Lung cancer
3	Long-Term Safety and Efficacy of Vismodegib in Patients With Advanced Basal Cell Carcinoma (aBCC): 18-Month Update of the Pivotal ERIVANCE BCC Study Aleksandar Sekulic,1 Michael R. Migden,2 Nicole Basset-Seguin,3 Claus G Add to Reading List Source URL: www.curis.com Language: English - Date: 2014-05-12 19:51:30 Chemistry Sulfones Vismodegib Basal-cell carcinoma End point of clinical trials Medicine Oncology Organochlorides
4	New target: FGFR & c-MET Laurence Albiges Gustave Roussy Institute, Dana-Farber Cancer Institute New target : FGFR, c-MET Add to Reading List Source URL: www.euikcs.com Language: English - Date: 2015-05-04 13:05:47 Organofluorides Angiology Growth factors Tyrosine kinase inhibitors Pyridines Vascular endothelial growth factor Sunitinib End point of clinical trials Sorafenib Chemistry Organic chemistry Biology
5	PUBLIC SUMMARY DOCUMENT Product: Imatinib, tablet, 100 mg and 400 mg (as mesylate), Glivec® Sponsor: Novartis Pharmaceuticals Australia Pty Ltd Date of PBAC Consideration: NovemberPurpose of Application Add to Reading List Source URL: www.pbs.gov.au Language: English - Date: 2014-10-01 21:56:22 Pyrimidines Gastrointestinal cancer Gastrointestinal stromal tumor Imatinib Chronic myelogenous leukemia Dermatofibrosarcoma protuberans End point of clinical trials Leukemia Medicine Oncology Piperazines
6	PUBLIC SUMMARY DOCUMENT Product: Ipilimumab, concentrate solution for I.V. infusion, 50 mg in 10mL, 200 mg in 40 mL, Yervoy® Sponsor: Bristol-Myers Squibb Australia Pty Ltd Date of PBAC Consideration: November. Add to Reading List Source URL: www.pbs.gov.au Language: English - Date: 2014-10-01 21:56:22 Melanoma Research Health Clinical research Pharmacology Clinical trial End point of clinical trials Medical statistics Bristol-Myers Squibb Ipilimumab
7	ABRAXANE® PLUS GEMCITABINE DEMONSTRATES SURVIVAL ADVANTAGE IN PHASE III STUDY OF PATIENTS WITH ADVANCED PANCREATIC CANCER Abraxane plus gemcitabine was superior to gemcitabine alone with statistically significant and cl Add to Reading List Source URL: www.pancreaticcancerindia.com Language: English - Date: 2013-02-05 05:27:34 Benzamides Breast cancer Bristol-Myers Squibb Eli Lilly and Company Gemcitabine Organofluorides Pancreatic cancer End point of clinical trials Protein-bound paclitaxel Chemistry Organic chemistry Medicine
8	DOCX Document Add to Reading List Source URL: www.pbs.gov.au Language: English - Date: 2015-04-22 23:39:46 Health economics B-cell chronic lymphocytic leukemia Lymphocytic leukemia Lymphoma Orphan drugs Leukemia Chlorambucil End point of clinical trials Rituximab Medicine Oncology Health
9	What is...? series New title Statistics Add to Reading List Source URL: www.medicine.ox.ac.uk Language: English - Date: 2009-07-07 06:57:02 Epidemiology Hazard ratio Relative risk Logrank test Proportional hazards models End point of clinical trials Docetaxel Head and neck cancer Randomized controlled trial Statistics Medical statistics Survival analysis
10	Microsoft Word - pomalidomide-psddocx Add to Reading List Source URL: www.pbs.gov.au Language: English - Date: 2015-04-22 23:39:46 Medical statistics Lenalidomide Orphan drugs Multiple myeloma Bortezomib Dexamethasone Thalidomide End point of clinical trials Celgene Medicine Health Immunosuppressants

UPDATE